MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs

Summary Fortress Biotech, through its subsidiary Cyprium Therapeutics, has completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million following the FDA approval of ZYCUBO (copper histidinate) for Menkes disease. The transaction represents a significant non-dilutive financing event and reinforces…